Polycythemia Vera - Part 1
From May 2019, This Mailbag is About to Rupture!Polycythemia vera is a relatively rare myeloproliferative disorder characterized by increased RBC production. In this segment, our own Matt DeClerck interviews Hematology guru Dr. Tom Deloughery on the in’s and out’s of PV. Clinical suspicion for PV should occur in any patient with elevated RBC …
21min 1Tom Deloughery, MD and Matthieu DeClerck, MD
Polycythemia Vera - Part 2
From May 2019, This Mailbag is About to Rupture!Polycythemia vera is a relatively rare myeloproliferative disorder characterized by increased RBC production. In this segment, our own Matt DeClerck interviews Hematology guru Dr. Tom Deloughery on the in’s and out’s of PV. Clinical suspicion for PV should occur in any patient with elevated RBC …
10min 34Tom Deloughery, MD and Matthieu DeClerck, MD
DOAC Reversal
From February 2019, Into Thin HairContinuing the recent discussion between Matt DeClerck and Dr. Tom Deloughery on the direct oral anticoagulants (DOACs), this month we bring you a segment on reversing these DOACs with Matt, Neda, and Dr. Tarlan Hedayati. What are the agents currently on the market, including the newest kid on the …
20min 52Tarlan Hedayati, MD, Neda Frayha, MD, and Matthieu DeClerck, MD
Eosinophilia
From February 2019, Into Thin HairWhat to do when you notice incidental eosinophilia in a patient? In this segment, Tom walks Neda through a fascinating case of peripheral eosinophilia, what it means, and how to work it up in the most strategic, effective way.
15min 18Tom Robertson, MD and Neda Frayha, MD
Clots and OCPs
From December 2018, Clots and OCP'sOur listeners are always asking for more Hematology content. They are also always asking for more Ob/Gyn content! In this segment, Neda and Rob address the two together with a few cases featuring both hypercoagulability and contraception.
10min 23Rob Orman, MD and Neda Frayha, MD
Sickle Cell Emergencies
From December 2018, Clots and OCP's1 in 5000 Americans has sickle cell disease, and these patients are at high risk for a variety of complications. Mizuho sits down with Jessica Osterman and Katie Harter to discuss sickle cell disease, pain crisis and emergencies.
21min 48Katherine Harter, MD, Jess Osterman, MD, and Mizuho Morrison, DO
Superficial Thrombophlebitis
From November 2018, Those Clots are So SuperficialWhen PC RAP listener Lisa wrote us that she’s observed different clinicians manage superficial thrombophlebitis in lots of different ways, from doing absolutely nothing to serial ultrasound to anticoagulation, our own Rob Orman couldn’t wait to put his love of hematology to use. In this segment, he …
11min 25Rob Orman, MD and Neda Frayha, MD
Anticoagulation with the DOACs
From October 2018, My Pancreas is Necrosing!It’s time for Hematology Rounds with Dr. Tom DeLoughery! In this segment, he and our own Matt DeClerck review the indications for and potential benefits and pitfalls of the direct oral anticoagulants (DOACs).
31min 9Tom Deloughery, MD and Matthieu DeClerck, MD
Paper Chase #4 | Ferrous Sulfate vs Iron Polysaccharide Complex in Kids with IDA
From April 2018, Will You Be My Facebook Friend?Ferrous sulfate led to a greater increase in hemoglobin concentration at 12 weeks and higher rates of resolution of iron-deficiency anemia compared with iron polysaccharide complex. Good old, tried-and-true ferrous sulfate for the win.
5min 34Andrew Buelt, DO and Joe Weatherly, DO
DOACs for VTE in Cancer - Tom DeLoughery for the Win!
From March 2018, DOACs for VTE in Cancer - Tom DeLoughery for the Win!Tom DeLoughery predicted a new practice pattern in an earlier PC RAP and he turned out to be totally right, so we’re proud to say “you heard it here first.”
5min 28Andrew Buelt, DO
Cancer & Thrombosis
From February 2018, The Tragically Sore HipTom Deloughery shares his wisdom on all things cancer and thrombosis. First, he reviews why patients with cancer are more likely to have clots, then reviews some aspects of thrombosis that are unique to this population. Lastly, he discusses treatment standards, nuances and controversies.
18min 54Tom Deloughery, MD and Matthieu DeClerck, MD
The COMPASS Trial
From February 2018, The Tragically Sore HipThis branch of the COMPASS trial examined 3 anticoagulation strategies in patients with “stable atherosclerotic disease”: rivaroxaban 5mg BID, ASA 100mg od + placebo BID, ASA 100 BID + rivaroxaban 2.5 mg BID. Casey’s analysis focused on the ASA groups, not the NOAC alone group. He concludes that …
13min 36Casey Parker, MD
Hematology Rounds - Thrombocytopenia
From November 2017, Lytes and BitesDr. Deloughery reviews his approach to the incidental thrombocytopenia. He reviews the differential in sick and well appearing pt. He describes the major causes of thrombocytopenia and suggests a stepwise approach to evaluation.
14min 29Tom Deloughery, MD and Heidi James, MD
The Tools of Satan: IVC Filters
From October 2017, It's Bloody Halloween!More and more research is showing that inferior vena cava filters may just be the Tools of Satan. At least Hematologist Tom Deloughery thinks. In this chapter, Tom and Heidi discuss a recent article on the diminishing role of IVC filters in thrombosis management.
16min 30Tom Deloughery, MD and Heidi James, MD
Thrombosis in Transgendered Medicine
From September 2017, You Can Do It!!Dr. Deloughery (The Delorean as I like to call him) is back, and this time he’s reviewing what we know about thrombosis risk in transgendered patients on hormone therapy. Transgendered medicine as a discipline has grown exponentially in the past decade, but the hematologic consequences are still …
16min 8Tom Deloughery, MD and Heidi James, MD
Things I Do But Should I: Warfarin
From November 2016, Aspirin Loses Its TenureIn this chapter of things I do but should I: A patient with low INR, to bridge or not to bridge with heparin; How often should patients with stable INR be monitored; what’s the proper warfarin starting dose; when starting warfarin, do we need to bridge with heparin until the INR is therapeutic? •
16min 44Vanessa Cardy, MD and Adrien Selim, MD
Things I do But Should I: Fecal Occult Blood Testing
From October 2016, Running Toward LongevityDiscuss evidence based dietary and medication restrictions prior to fecal occult blood testing, based on the article by Konrad, Gerald, and Alan Katz. "Are medication restrictions before FOBT necessary? Practical advice based on a systematic review of the literature." Canadian Family Physician 58.9 …
13min 15Vanessa Cardy, MD and Adrien Selim, MD
Lead Poisoning
From September 2016, Best Weight, Best Exercise!From the Festival of Saturn in ancient Rome to the water supply in Flint, Michigan, lead toxicity has been a scourge of humanity for millennia. •
18min 9Stuart Swadron, MD FAAEM, Sean Nordt, MD PharmD FAAEM, and Rob Orman, MD
Anemia Deep Dive: Macrocytosis
From August 2016, Feeling RestlessThe final stop on our anemia deep dive. When the MCV gets over 100, it’s time to start looking for pathology.
21min 17Tom Deloughery, MD and Rob Orman, MD
The Hemolytic Anemias
From June 2016, C Diff Shows No Mercy!Sometimes an email isn't a problem of making blood, it;s a problem of breaking blood. •
19min 3Tom Deloughery, MD and Rob Orman, MD
‹ PreviousNext ›